Lucentis Versus Mitomycin C During Glaucoma Surgery

Completed · Phase 2/Phase 3

Conditions studied: Glaucoma

In brief

Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.

Key facts

Study ID

NCT00626782

Run by

Wills Eye

People needed

24

Starts

2008-01-01

Expected to finish

2011-04-01

Last updated by the study team

2018-03-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 yrs or older
• patients requiring first time glaucoma filtering surgery
• phakic or pseudophakic
• must provide written informed consent and comply with study assignments

You may not qualify if…

• Pregnant, lactation or premenopausal women not using adequate contraception.
• Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle, penetrating keratoplasty.
• Abnormality preventing reliable applanation tonometry in each eye.
• Current infection or inflammation in either eye.
• Enrolled in another investigational study.

Where it is running

• Wills Eye Hospital, Glaucoma Service — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.